logo
This temporary tattoo could warn you if your drink has been spiked

This temporary tattoo could warn you if your drink has been spiked

Yahoo5 days ago
For decades, 'protect your drink' has been one of the foundational unofficial rules of nightlife. The threat of unwittingly consuming a date-rape drug looms so large that steps to combat that risk have become a routine part of any night out. There are even new products designed specifically to defend against having a drink spiked.
That level of diligence is, unfortunately, necessary. While the nature of date-rape drugs makes it hard to track how frequently they are used, evidence suggests that millions of people are sexually assaulted every year after consuming drugs they took involuntarily.
Researchers in Korea have come up with a simple and effective idea that they hope will give people an easy new way to protect themselves. It's a temporary tattoo that can instantly detect the presence of one of the most common date-rape drugs from a single drop of a suspect drink. The tattoo is made with a mix containing a chemical receptor that reacts to even tiny amounts of gamma-hydroxybutyric acid (GHB) — an odorless, tasteless drug that is often used in what authorities call drug-facilitated sexual assault.
When the tattoo comes in contact with GHB, it changes color from yellow to red, providing a clear indication within one second that a beverage has been tampered with.
There are other products on the market that can be used to test drinks for GHB, along with other date-rape drugs like Rohypnol and ketamine, but they are difficult to use discreetly and can take up to five minutes to provide results. Someone wearing one of the tattoos, on the other hand, could easily dip their finger into their beverage, touch the tattoo and know right away whether it has been tampered with. All this can be done in secret because the tattoos can be made in any shape, so their true purpose won't be obvious to the people around you. The researchers behind the tattoos hope their innovation will one day provide a 'proactive and accessible solution' that will allow people to easily and subtly protect themselves.
According to a study published in the scientific journal ACS Sensors, the tattoos were consistently able to detect small amounts of GHB — as little as 0.01 micrograms in 1 milliliter of liquid — in a variety of beverages, including whiskey, vodka, beer, coffee and soju (a popular Korean alcoholic drink).
The tattoos could also prove useful after an assault has occurred, the researchers say. Authorities often struggle to determine whether a victim consumed a 'spiked' drink because common date-rape drugs stop being detectible in someone's system within a few hours and often can only be verified by a professional lab. But the tattoos can display a positive result for up to 30 days, which the researchers say 'could be important if it's needed as a form of evidence of tampering.'
So far, the tattoos have only been tested with GHB, but the researchers say the same system could likely be used to detect other drugs if different chemical receptors are added.
It's unclear when the tattoos might be available to the public, but the researchers said a commercial product could be on the market soon because the tattoos are inexpensive and easy to manufacture.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Polymyalgia Rheumatica Not Linked to Increased Mortality
Polymyalgia Rheumatica Not Linked to Increased Mortality

Medscape

time2 hours ago

  • Medscape

Polymyalgia Rheumatica Not Linked to Increased Mortality

TOPLINE: In a long-term follow-up study, patients with isolated polymyalgia rheumatica (PMR) and biopsy-confirmed giant cell arteritis (GCA) had no increased all-cause mortality compared with matched individuals; men with PMR showed lower mortality. METHODOLOGY: Researchers assessed long-term all-cause mortality in patients with PMR using data from a prospective, population-based inception cohort in Norway between 1987 and 1997 that was followed for 38 years. They included 274 patients with isolated PMR (mean age at diagnosis, 71.9 years; 66.1% women) and 63 patients with GCA (mean age at diagnosis, 71.6 years; 76.2% women), of whom 22 had coexisting PMR and GCA. PMR was defined with the fulfilment of criteria suggested by Bird and colleagues, and the diagnosis of GCA was confirmed with a positive temporal artery biopsy. Each case of PMR and GCA was matched with 15 individuals from the population registry on the basis of sex, age at inclusion, and residency, resulting in a total of 4110 and 945 individuals, respectively. Mortality and survival were assessed using the standard mortality ratio (SMR), with patients being followed up till death or until December 2024. TAKEAWAY: Among all patients with PMR, 96% had died by the end of the study, with a mean follow-up duration of 14 years and a maximum of 35.3 years. All-cause mortality in patients with PMR or GCA did not differ significantly from that in matched individuals. Men with PMR had significantly lower all-cause mortality (SMR, 0.77; 95% CI, 0.62-0.95); no significant sex-related differences were observed in patients with GCA. The overall cumulative survival in patients with PMR or GCA was not significantly different from that in the matched individuals. IN PRACTICE: "Our findings align with previous evidence reinforcing that isolated PMR does not sig­nificantly impact survival negatively, offering reassurance to both patients and clinicians regarding its long-term prognosis," the authors wrote. SOURCE: This study was led by Stig Tengesdal, Sørlandet Hospital, Kristiansand, Norway. It was published online on July 21, 2025, in Arthritis Research & Therapy. LIMITATIONS: The Bird's criteria may have relatively poor specificity for PMR. The prevalence of large vessel vasculitis may have been underestimated in the PMR cohort. Cases of malignancy could not be identified and excluded as data from medical charts were limited. DISCLOSURES: This study did not receive any specific funding. The authors declared having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Older Breast Cancer Patients Face Inconsistent Bone Care
Older Breast Cancer Patients Face Inconsistent Bone Care

Medscape

time2 hours ago

  • Medscape

Older Breast Cancer Patients Face Inconsistent Bone Care

TOPLINE: Bone health management for older women with breast cancer receiving aromatase inhibitors (AIs) varied substantially across five UK hospitals. Despite the higher risk for fractures, women older than 80 years were less likely to receive DEXA scans or bisphosphonates, highlighting the urgent need for standardised bone monitoring and treatment in frail older patients. METHODOLOGY: This secondary analysis of the multicentre Age Gap study included 529 women (age, ≥ 70 years) with oestrogen receptor-positive early breast cancer who received AIs, either as primary or adjuvant treatment, at five hospitals in the UK. Researchers collected comprehensive data including the type of endocrine therapy, DEXA scan results, bisphosphonate usage, calcium and vitamin D supplementation, and the incidence of fractures during or after AI therapy. Frailty was assessed using a modified Rockwood Frailty Index, with scores being calculated across 75 variables to categorise patients as robust (< 0.08), prefrail (0.08-0.25), or frail (> 0.25). TAKEAWAY: Overall, 67% of patients had baseline DEXA scans. Of these, 42% were osteopenic and 18% osteoporotic. Scans were more common in 70- to 79-year-olds than in those aged 80 years or older and in women undergoing surgery than in those undergoing primary endocrine therapy, with marked variation across centres (P < .001 for all). Among patients receiving AI therapy, 43% were prescribed bisphosphonates, especially those who had surgery (hazard ratio [HR], 1.36; P = .04) and those aged 70-79 years (HR, 1.31; P = .02); 33% had vitamin D plus calcium along with bisphosphonates. During follow-up, 23% of patients had fractures, with significant variation across centres (P = .02), and 38% of these patients had received prior bisphosphonates. Although 94% of patients were frail or prefrail, frailty did not correlate with baseline hip (P = .10) or spine (P = .89) T scores. Bisphosphonates plus AIs were prescribed in 70% of non-frail participants vs 43% of prefrail and 47% of frail participants (P = .02). IN PRACTICE: "Patient's age and general health influence bone health decision making, with older and frailer patients often receiving non-standard care. Despite national and international recommendations, there is still wide variation in bone health management, highlighting the need for further education and standardised bone health care in older women with breast cancer," the authors wrote. SOURCE: This study was led by Elisavet Theodoulou, University of Sheffield, Sheffield, England. It was published online on July 18, 2025, in the Journal of Geriatric Oncology. LIMITATIONS: The study's inclusion of only five hospital sites limited the ability to draw broader conclusions about bone health management practices across a wider range of centres. Additionally, the interpretation of the results was complicated by the introduction of adjuvant bisphosphonates during the study period, making the cohort unstable in terms of bisphosphonate usage indications. DISCLOSURES: The Age Gap study was supported by the National Institute for Health and Care Research Programme Grants for Applied Research. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Low Vitamin D May Raise COVID-19 Hospitalisation Risk
Low Vitamin D May Raise COVID-19 Hospitalisation Risk

Medscape

time2 hours ago

  • Medscape

Low Vitamin D May Raise COVID-19 Hospitalisation Risk

TOPLINE: An analysis of over 150,000 participants found that insufficient and deficient levels of vitamin D were associated with an increased risk for COVID-19 hospitalisation but not with the risk for COVID-19 infection; however, no significant associations were found among participants with a prior cancer diagnosis. METHODOLOGY: Researchers in London used data from the UK Biobank cohort to assess the association between levels of vitamin D (insufficient and deficient vs normal) and both COVID-19 infection and hospitalisation. They included a total of 151,543 participants (mean age, 56 years; 53% women), with a subset of 24,400 participants diagnosed with cancer prior to 2019. Serum vitamin D levels were measured at baseline between 2006 and 2010 (deficiency, < 24 nmol/L; insufficiency, 25-50 nmol/L; and normal, > 50 nmol/L); all had at least one positive COVID-19 polymerase chain reaction test. Endpoints were first COVID-19 infection (measured using the positive polymerase chain reaction test result) and COVID-19 hospitalisation (measured using hospital admission records). TAKEAWAY: Among overall participants, 14% had at least one positive COVID-19 test result, of whom 11% were hospitalised; in the cancer cohort, 11% of participants tested positive for COVID-19 and 14% of them were hospitalised. Vitamin D insufficiency and deficiency were associated with 19% and 36% higher odds of COVID-19 hospitalisation, respectively, than normal levels of vitamin D (P < .001 for both); however, no association was found between low levels of vitamin D and COVID-19 infection. Sensitivity analyses showed that among Black and Asian participants, low levels of vitamin D were linked to an increased risk for COVID-19 infection but not to increased hospitalisation rates. Among the subset of patients with cancer, levels of vitamin D were not significantly associated with COVID-19 outcomes. IN PRACTICE: "[The study] results highlight the complex role of VitD [vitamin D] in COVID-19 outcomes and the varying impact it has across different population subgroups," the authors wrote. SOURCE: This study was led by Maria J. Monroy-Iglesias, Transforming Outcomes through Research, Centre for Cancer, Society, and Public Health, School of Cancer and Pharmaceutical Sciences, King's College London, London, England. It was published online on July 18, 2025, in PLoS One. LIMITATIONS: Vitamin D levels were measured at baseline (between 2006 and 2010) over a decade before the COVID-19 pandemic, which may have led to the misclassification of participants' vitamin D status. This study could not account for seasonal variations in vitamin D levels. Subgroup analyses were limited by small sample sizes. The study cohort was not fully representative of the UK population, and potential bias may have arisen from differential access to COVID-19 testing. DISCLOSURES: This study did not receive any specific funding. The authors declared having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store